Weekly Research Analysts’ Ratings Changes for Benitec Biopharma (BNTC)

A number of firms have modified their ratings and price targets on shares of Benitec Biopharma (NASDAQ: BNTC) recently:

• 8/1/2026 – Benitec Biopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/28/2026 – Benitec Biopharma is now covered by Wedbush. They set an “outperform” rating and a $16.00 price target on the stock.
• 7/28/2026 – Benitec Biopharma is now covered by Wedbush. They set an “outperform” rating and a $16.00 price target on the stock.
• 7/17/2026 – Benitec Biopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/13/2026 – Benitec Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/10/2026 – Benitec Biopharma was downgraded by Guggenheim from “buy” to “neutral”.

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.